0,1,2,3,4,5
Table 28: Summary of clinical evidence of PTT as monotherapy,,,,,
Author/year,Study type,Device,"No. of 
patients",Hours of use,Result
Levine et al. (2008),"Pilot 
Prospective, 
uncontrolled",Fast Size®,10,"2-8h
6 months","Mean reduction in PC 
33% (51º-34º) 
SPL: + 0.5-2 cm 
EG: + 0.5-1 cm 
IIEF: + 5.3"
"Gontero et al. 
(2009)","Phase II 
Prospective 
Uncontrolled",Andropenis®,15,"> 5h 
6 months","Mean reduction in PC: 
N/S 
SPL: + 0.8 cm (6 mo) 
+ 1.0 cm (12 mo)"
"Martinez-
Salamanca et al. 
(2014)","Prospective, 
controlled, open 
label 
Men in AP",Andropenis®,"96 
55 (PD) 
41 (NIG)","6-9h (4.6 h/d) 
6 months","Mean reduction in PC: 
20º (33º-15º) p < 0.05. 
SPL: + 1.5 cm (6 mo) 
EG: + 0.9 cm (6 mo)"
"Moncada el al. 
(2018)","Controlled 
multicenter trial 
Men in CP",Penimaster®PRO,"80 
41 (PTT) 
39 (NIG)","3-8h 
3 months","Mean reduction in PC: 
31º (50º-15º). 
SPL: + 1.8 cm (3 mo) 
EG: + 0.9 cm (6 mo) 
IEEF: + 2.5"
"Ziegelmann et al. 
(2019) [1142]","Randomised, 
prospective, 
controlled, single 
blind study 
Men in CP and 
contols 3:1",Restorex®,110,"30-90 min/day 
3 months","Mean reduction in PC 
(3 mo): 13.3º (PTT) 
+ 1.3º (control)  
p < 0.001 
SPL: + 1.5 cm (PTT) + 
0 cm (control)  
p < 0.001 
IIEF: + 4.3 (PTT) -0.7 
(control) p = 0.01"
